Basel Medical Group Ltd (NASDAQ:BMGL) concluded the trading at $1.75 on Friday, June 27 with a fall of -2.78% from its closing price on previous day.
Taking a look at stock we notice that its last check on previous day was $1.8 with its price kept floating in the range of $1.7101 and $2.1496 on the day. Company’s P/E ratio for the trailing 12 months is 82.16. Considering stock’s 52-week price range provides that BMGL hit a high price of $9.40 and saw its price falling to a low level of $0.91 during that period. Over a period of past 1-month, stock came adding 71.57% in its value.
With its current market valuation of $32.88 million, Basel Medical Group Ltd is set to declare its quarterly results in July. Analysts are in estimates of 0 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to 0 for current year with estimates of that growing to 0 in next year.
Digging deeper we become aware of the PEG ratio of the BMGL stock which is currently positioned at 0. It further provides that stock’s current price level is -49.88% away from its 20-day simple moving average and is -49.25% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 38.51 while volatility remained at 18.07% over the past week which changes to 53.93% when measuring it over the past month.
Having a second look at Basel Medical Group Ltd (NASDAQ:BMGL) provides that stock’s average daily trading volume for 3 months was 5.51 million, while it jumped to 877950 when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 18.75 million.
The figures also indicate that as of 2025-06-13, number of stock’s short shares was 0.44 million which implies a short ratio of 0.03. This shows up a 509.00 of Short Interest in company’s outstanding shares on the day. In June the standing of shares short improved as it was 0.29 million in the previous month.
